InsideSales.com to acquire VC-backed C9

InsideSales.com is planning on buying San Mateo, California-based C9 Inc, a provider of predictive analytics. No financial terms were disclosed. C9’s backers include Mayfield Fund, InterWest Partners and Leapfrog Ventures.

InterWest Partners appoints Alta’s Champsi as MD

InterWest Partners has named Farah Champsi as a managing director. Currently, Champsi is a managing director at Alta. Prior to that, Champsi served as head of global life sciences investment banking at Robertson Stephens & Company.


VC-backed Glaukos Corp files for IPO

Laguna Hills, California-based Glaukos Corporation, a developer of treatments for glaucoma, has filed for an IPO. The number of shares that will be sold as well as the IPO’s pricing terms have yet to be set. The company plans on trading the stock on the NYSE under the ticker symbol “GKOS.” J.P. Morgan, BofA Merrill Lynch and Goldman, Sachs & Co are serving as the lead underwriters. Glaukos’ backers include OrbiMed Advisors, Frazier Healthcare Ventures, InterWest Partners, Domain Associates, Fjord Ventures, Montreaux Equity Partners and Versant Ventures

VC-backed Cidara Therapeutics rolls out IPO

San Diego-based biotech company Cidara Therapeutics has raised $76.8 million for its IPO after pricing its 4.8 million shares at $16 per share. The stock begins trading Wednesday on the NASDAQ under the ticker symbol “CDTX.” Jefferies LLC and Leerink Partners are the lead underwriters. Cidara’s backers include 5AM Ventures, Aisling Capital, Frazier Healthcare and InterWest Partners.

VC-backed Carbylan Therapeutics rolls out IPO

Palo Alto, California-based Carbylan Therapeutics, a pharmaceutical company focused on developing treatments that “address significant unmet clinical needs,” has raised $65 million in its IPO after pricing its 13 million shares at $5 per share. The stock began trading Thursday on the NASDAQ under the ticker symbol “CBYL.” Leerink Partners LLC is serving as lead underwriter. The company’s backers included InterWest Partners, Alta Partners and Vivo Ventures.


Industry Ventures leads $40 mln round for The RealReal

Luxury resale site The RealReal has secured $40 million in Series D funding. Industry Ventures led the round with participation from other investors that included e.ventures Growth, Greycroft Growth, DBL Partners, Canaan Partners and InterWest Partners. In addition to the funding, Cynthia Ringo of DBL Partners has been added to The RealReal’s board of directors.

Pivot3 raises $45 mln

Pivot3 said Tuesday that it closed a $45 million equity and bank financing round. Argonaut Private Equity, a new investor in Pivot3, joined S3 Ventures, InterWest Partners, Mesirow Financial Private Equity and the Wilson Sonsini Goodrich & Rosati investment fund in providing additional equity. Austin-based Pivot3 develops hyper-converged infrastructure solutions.


Invuity pulls in $20 million in Wellington-led round

San Francisco-based Invuity Inc, a surgical photonics company, has closed $20 million in funding. Wellington Management LLP led the round with participation from other investors that included HealthCare Royalty Partners, Valence Life Sciences, InterWest Partners and Kleiner Perkins Caufield & Byers.


Obalon Therapeutics nabs $30 mln

San Diego-based Obalon Therapeutics, a developer of gastric balloon technology for weight loss therapy, has received $20 million in Series D funding and a $10 million loan from Square 1 Bank. The Series D investors included Axon Ventures, Mirae Asset Venture Investment, Striker Asia Opportunities Fund, Domain Associates, InterWest Partners and Okapi Venture Capital.


Welltok scores $37 mln Series D

Denver-based health optimization firm Welltok has closed its Series D funding round at $37 million. Bessemer Venture Partners led the round with participation from other investors that included Hearst Health Ventures, Catholic Health Initiatives, Emergence Capital Partners, InterWest Partners, New Enterprise Associates and Qualcomm Ventures.


InVisage Technologies snaps up $32.5 mln

Menlo Park, Calif.-based camera platform InVisage Technologies has received $32.5 million in funding. The investors in this round included China Oceanwide USA Holdings, GGV Capital, Nokia Growth Partners, InterWest Partners, Intel Capital and RockPort Capital.

PMV Pharmaceuticals grabs $30 mln

PMV Pharmaceuticals, which develops p53 targeted small molecule drugs to treat cancer, has raised $30 million in Series A financing. OrbiMed led the round with participation from Osage University Partners and supported by founding investor InterWest Partners. In addition to the funding, Dr. Peter Thompson of OrbiMed has been appointed to PMV’s board of directors.


Stellar Loyalty inks $5 mln Series A

Stellar Loyalty has closed $5 million in Series A funding. InterWest Partners led the round. Based in in Foster City, Calif. and Manila, Stellar Loyalty is a provider of cloud-based big data customer loyalty solutions.


Appboy grabs $15 mln Series B

Appboy said Thursday that it has secured $15 million in Series B funding. InterWest Partners led the round with participation from previous backers Icon Venture Partners, Blumberg Capital, T5 Capital and IDG Ventures. In addition to the funding, Doug Pepper, general partner at InterWest, has been appointed to Appboy’s board of directors. Based in New York City, Appboy is a provider of marketing automation for apps.


S3 Ventures led $12 mln round for Pivot3

Pivot3 has raised $12 million in funding round. S3 Ventures led the round with participation from return backers InterWest Partners and Mesirow Financial. Also, the firm has hired Mike Dansby as vice president and chief financial officer. Based in Austin, Texas, Pivot3 is a provider of data storage solutions.


VC-backed Tapjoy acquires 5Rocks

Mobile app tech firm Tapjoy has bought 5Rocks. No financial terms were disclosed. 5Rocks is a Korean provider of predictive analytics and marketing automation solutions. Tapjoy is backed by J.P. Morgan Asset Management, Rho Ventures, North Bridge Venture Partners, InterWest Partners and D.E. Shaw Ventures.


Cidara Therapeutics snags $32 mln Series A

Biopharmaceutical firm Cidara Therapeutics said Monday that it has secured $32 million in Series A funding. 5AM Ventures, Aisling Capital, Frazier Healthcare and InterWest Partners were the lead investors. In addition to the financing, the firm has hired Dr. Jeffrey Stein as president and CEO. It has also named Dr. Kevin Judice and Dr. H. Shaw Warren as chief operating officer and chief scientific officer respectively. Warren will also join Cidara’s scientific advisory board.  And, Dr. Ken Bartizal has been added as chief development officer while Dr. Dirk Thye has joined Cidara as chief medical officer.


Teva agrees to buy VC-backed Labrys for up to $825 mln

sraeli pharmaceutical company Teva Pharmaceutical Industries has agreed to acquire Labrys Biologics for $200 million in upfront payment in cash as well as up to $625 million in payments based on achievement of certain pre-launch milestones. Based in San Mateo, Calif., Labrys is a biotech firm focused on treating migraine. It was backed by venBio, Canaan Partners, InterWest Partners and Sofinnova Ventures.

PE HUB Community

Join the 12519 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget